MONTREAL, Aug. 5, 2014 /CNW/ -- Paladin Labs Inc., a
subsidiary of Endo International plc (NASDAQ: ENDP)
(TSX: ENL), announced today the launch of Travelan®, a unique
over-the-counter product to help reduce the risk of travellers'
diarrhea.
Travelan® is clinically proven to provide protection against the
main cause of travellers' diarrhea in 90% of consumers who use
it1. Travelan® is a convenient option for all those
travelling to at-risk regions such as Central and South America, Mexico, Africa, the Middle
East and Asia. It does not
require a prescription, and is not associated with any significant
side effects.
It is estimated that there are over 5 million trips made by
Canadians to at-risk regions every year2. One-in-three
Canadian vacationers have experienced, or have travelled with
someone who has experienced, travellers' diarrhea3.
Sources of Enterotoxigenic Escherichia Coli (ETEC) bacteria, which
cause the majority of cases of travellers' diarrhea4,
can include poorly cooked meat, contaminated raw vegetables or
unpasteurized dairy products. Given that no food group can be
regarded as "safe"4, research demonstrates that
three-quarters of Canadians have indicated that they would take a
preventive for travellers' diarrhea3.
"We are pleased to announce the launch of Travelan® in
Canada," said Mark Beaudet, President of Paladin Labs Inc.
"This option responds to the clear market need for a clinically
proven, accessible option to help reduce the risk of travellers'
diarrhea."
Paladin obtained the exclusive rights to market and sell
Travelan® in Canada,
Latin America (including
Brazil and Mexico) and Sub-Saharan Africa (including
South Africa) from Immuron Ltd
(ASX:IMC) in November 2011.
About Travelan®
Travelan® is a natural product which is specifically
designed to reduce the risk of infection by ETEC, the most common
cause of travellers' diarrhea. In clinical trials,
Travelan® showed efficacy of up to 90% in protecting
against infection with the type of E.Coli that causes travellers'
diarrhea. In addition, trials showed a significant reduction in
abdominal cramps and stomach pain compared to those who did not
receive Travelan®. There were no reported
treatment-related side effects in the clinical trials.
For more information, please visit
www.travelancanada.ca
Suggested retail price: $29.99-39.99 (pack of 30 tablets).
Available on pharmacy shelves.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing
innovative pharmaceutical products for the Canadian market. Paladin
has a focused marketing and sales organization that has helped it
evolve into one of Canada's
leading specialty pharmaceutical companies. Paladin is an operating
company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a
global specialty healthcare company focused on improving patients'
lives while creating shareholder value. Learn more at
www.endo.com.
References
1 Travelan Product Packaging, 2013.
2 Statistics Canada,
International Travel 2010, Catalogue no. 66-201-X.
3 Leger Marketing, State of Vacation: Canadians
Perspectives on Travellers' Diarrhea, October 2011.
4 Public Health Agency of Canada, Canada Communicable Disease Report:
Statement on Travellers' Diarrhea, 15 March
2001.
Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and Canadian securities legislation. Statements including words
such as "believes," "expects," "anticipates," "intends,"
"estimates," "plan," "will," "may," "look forward," "intend,"
"guidance," "future" or similar expressions are forward-looking
statements. Because these statements reflect Endo's current views,
expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties.
Although Endo believe that these forward-looking statements and
information are based upon reasonable assumptions and expectations,
readers should not place undue reliance on them, or any other
forward-looking statements or information in this news release.
Investors should note that many factors, as more fully described in
the documents filed by Endo and Endo Health Solutions Inc. ("EHSI")
with securities regulators in the United
States and Canada including
under the caption "Risk Factors" in EHSI's Form 10-K, and Endo's
Form 10-Q and Form 8-K filings, as applicable, with the Securities
and Exchange Commission and by Endo with securities regulators in
Canada on the System for
Electronic Document Analysis and Retrieval ("SEDAR") and as
otherwise enumerated herein or therein, could affect Endo's future
financial results and could cause Endo's actual results to differ
materially from those expressed in forward-looking statements
contained in EHSI's Annual Report on Form 10-K. The forward-looking
statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate,
could cause Endo's actual results to differ materially from
expected and historical results. Endo does not assume any
obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise, except as may be required under applicable securities
law.
SOURCE Endo International plc